Literature DB >> 1971660

Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.

O Wiklund1, B Angelin, S O Olofsson, M Eriksson, G Fager, L Berglund, G Bondjers.   

Abstract

Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2.5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n = 48) than in those without (n = 72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971660     DOI: 10.1016/0140-6736(90)91242-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

1.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Lipoprotein (a): a possible link between lipoprotein metabolism and thrombosis.

Authors:  A Rees
Journal:  Br Heart J       Date:  1991-01

Review 3.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 4.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

5.  Simvastatin in severe hypercholesterolaemia: a placebo controlled trial.

Authors:  I F McDowell; M Smye; T Trinick; J A Shortt; M P Archibald; E R Trimble; D P Nicholls
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

7.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

8.  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

9.  Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia.

Authors:  G F Watts; E M Kearney; N A Taub; B M Slavin
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

10.  Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.

Authors:  D J Rader; W Cain; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.